Shoulder Innovations (SI) Shares Advance 3.31 % in Friday Trading
Date: Friday, 23 April 2026Time of Reference: 11:04 AM Central European Time
Market Performance
- Closing Price (11:04 AM CET): USD 19.75
- Percentage Gain: +3.31 % within the 24‑hour period ending at the reference time.
- Trading Volume (last 24 h): USD 3 million worth of shares were traded.
- Market Capitalisation: USD 411.2 million.
Technical Indicators
- 200‑Day Simple Moving Average (SMA): USD 16.82
- 52‑Week High: USD 24.60 (recorded on 29 July 2026)
- 52‑Week Low: USD 10.92 (recorded on 11 November 2025)
Comparative Performance of Related Stocks
| Symbol | Company | 24‑Hour Change | Current Price | Market Capitalisation |
|---|---|---|---|---|
| MNPR | Monopar Therapeutics | –2.53 % | USD 72.58 | USD 485.6 million |
| UAMY | United States Antimony | –5.78 % | USD 3.10 | USD 492.4 million |
| AAC | Ares Acquisition Cl | +0.10 % | USD 10.05 | USD 492.7 million |
| EOLS | Evolus | +0.41 % | USD 7.41 | USD 488.8 million |
| CBIO | Crescent Biopharma | –0.23 % | USD 13.14 | USD 489.2 million |
Summary
Shoulder Innovations (SI) experienced a notable gain of 3.31 % during the trading window ending at 11:04 AM CET on Friday, 23 April 2026. The stock closed at USD 19.75, reflecting a significant rise compared to the previous day. The company’s market capitalisation stands at USD 411.2 million, with a 24‑hour trading volume of approximately USD 3 million. Technical metrics indicate the stock trades above its 200‑day simple moving average (USD 16.82) and remains within a healthy range relative to its 52‑week high and low.
In comparison, several peer companies in the same reporting period exhibited mixed performance: Monopar Therapeutics and United States Antimony declined, while Ares Acquisition Cl, Evolus, and Crescent Biopharma showed modest gains or minor declines.